CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,291,437 | -29.2% | 517,244 | +3.0% | 0.00% | -40.0% |
| Q2 2023 | $15,958,039 | +34.4% | 501,983 | +3.1% | 0.01% | +25.0% |
| Q1 2023 | $11,877,516 | -22.4% | 486,983 | +0.3% | 0.00% | -20.0% |
| Q4 2022 | $15,307,750 | +15.8% | 485,344 | +3.8% | 0.01% | 0.0% |
| Q3 2022 | $13,220,000 | +26.4% | 467,786 | +18.3% | 0.01% | +25.0% |
| Q2 2022 | $10,457,000 | -19.8% | 395,485 | +6.2% | 0.00% | 0.0% |
| Q1 2022 | $13,044,000 | +10.8% | 372,561 | +2.6% | 0.00% | +33.3% |
| Q4 2021 | $11,773,000 | +13.4% | 363,120 | +3.2% | 0.00% | 0.0% |
| Q3 2021 | $10,379,000 | +61.1% | 351,808 | +39.9% | 0.00% | +50.0% |
| Q2 2021 | $6,444,000 | +173.3% | 251,493 | +46.5% | 0.00% | +100.0% |
| Q1 2021 | $2,358,000 | -14.7% | 171,670 | +3.0% | 0.00% | 0.0% |
| Q4 2020 | $2,765,000 | – | 166,710 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |